Hangauer et al. found that the survival of therapy-resistant high-mesenchymal cancers relied on the activity of GPX4 [40] and is especially vulnerable to ferroptosis inducers (sorafenib, erastin, and sulfasalazine); the underlying mechanism is that metadherin (MTDH) conferred to this therapy-resistant cell state and sensitizes cells to ferroptosis inducer by decreasing GPX4 and SLC3A2 expressions [41]. Here, GPX4 is linked to cancer.